Baidu
map

JAHA:冠状病毒疾病的心血管并发症研究

2020-07-16 MedSci原创 MedSci原创

本荟萃分析的目的旨在探讨COVID-19、SARS和MERS患者心血管并发症的患病率。

本荟萃分析的目的旨在探讨COVID-19、SARS和MERS患者血管并发症的患病率。

本研究纳入分析了22个临床研究(12个COVID-19、4个SARS和6个MERS),COVID-19、SARS和MERS患者的平均年龄分别为46.41±1.79岁、39.16±2.25岁和52.51±4.64岁。冠状病毒性疾病心血管并发症的比例如下:COVID-19:高血压的比例为17.1%(95%CI为13.2-20.9%),心脏病的比例为4.5%(95%CI为3.6-5.5%),糖尿病的比例为8.5%(95%CI为5.5-11.4%);SARS:高血压的比例为4.5%(95%CI为2.0-7.0%),心脏病的比例为2.1%(95%CI为0.6-3.7%),糖尿病的比例为3.7%(95%CI为1.0-6.4%);MERS:高血压的比例为30.3%(95%CI为18.3-42.2%),心脏病的比例为20.9%(95%CI为10.7-31.1%),糖尿病的比例为45.4%(95%CI为27.3-63.5%)。

研究结果显示,不同冠状病毒疾病的心血管并发症比例也有所不同,随着时间的推移,COVID-19心血管并发症的比例需要进一步关注。

原始出处:

Yang L et al.The prevalence of cardiovascular comorbidities in COVID‐19, SARS and MERS: pooled analysis of published data.JAHA.2020 July.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1758259, encodeId=41e21e58259d2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Apr 05 20:47:53 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806739, encodeId=197c806e3949, content=这个杂志投稿周期多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Aug 07 09:45:05 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268291, encodeId=7fe41268291a3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515117, encodeId=fba6151511eb2, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=205, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545373, encodeId=119d15453e378, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=)]
    2021-04-05 丁鹏鹏
  2. [GetPortalCommentsPageByObjectIdResponse(id=1758259, encodeId=41e21e58259d2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Apr 05 20:47:53 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806739, encodeId=197c806e3949, content=这个杂志投稿周期多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Aug 07 09:45:05 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268291, encodeId=7fe41268291a3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515117, encodeId=fba6151511eb2, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=205, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545373, encodeId=119d15453e378, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=)]
    2020-08-07 咻凡

    这个杂志投稿周期多久?

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1758259, encodeId=41e21e58259d2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Apr 05 20:47:53 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806739, encodeId=197c806e3949, content=这个杂志投稿周期多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Aug 07 09:45:05 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268291, encodeId=7fe41268291a3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515117, encodeId=fba6151511eb2, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=205, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545373, encodeId=119d15453e378, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=)]
    2020-07-18 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1758259, encodeId=41e21e58259d2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Apr 05 20:47:53 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806739, encodeId=197c806e3949, content=这个杂志投稿周期多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Aug 07 09:45:05 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268291, encodeId=7fe41268291a3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515117, encodeId=fba6151511eb2, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=205, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545373, encodeId=119d15453e378, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1758259, encodeId=41e21e58259d2, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Mon Apr 05 20:47:53 CST 2021, time=2021-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=806739, encodeId=197c806e3949, content=这个杂志投稿周期多久?, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b58d5402080, createdName=咻凡, createdTime=Fri Aug 07 09:45:05 CST 2020, time=2020-08-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268291, encodeId=7fe41268291a3, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1515117, encodeId=fba6151511eb2, content=<a href='/topic/show?id=049251e9368' target=_blank style='color:#2F92EE;'>#心血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=205, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51793, encryptionId=049251e9368, topicName=心血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a8b10715402, createdName=zywlvao, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545373, encodeId=119d15453e378, content=<a href='/topic/show?id=a803896303f' target=_blank style='color:#2F92EE;'>#血管并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89630, encryptionId=a803896303f, topicName=血管并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b67913724176, createdName=ms3892185887221420, createdTime=Sat Jul 18 01:47:53 CST 2020, time=2020-07-18, status=1, ipAttribution=)]

相关资讯

JACC:PRKAG2综合征的临床特征和自然病程研究

PRKAG2基因变异可导致一种以心肌病、传导疾病和心室预激为特征的综合征,到目前为止,只有少数病例报告,对该病的自然史了解甚少。本研究的目的是在一个大型多中心欧洲队列中描述PRKAG2变异的表型和自然

盘点:JACC七月第2期研究一览

1. 阿利昔单抗对纯合子家族性高胆固醇血症患者的疗效研究

JACC:出院后出血与急性心梗患者死亡率相关

在未经皮冠状动脉介入治疗(PCI)的急性冠脉综合征(ACS)患者中,出院后出血的长期预后影响尚不清楚。本研究的目的是根据治疗策略(PCI或非PCI)评估ACS患者出院后出血与随后死亡率之间的关系。

JACC:美国成年先心病患者的特征评估

在美国有超过100万名先心病成年人,本研究目的旨在评估年龄在20至64岁的先心病患者的人口统计学、并发症和医疗保健使用情况。

JAHA:成年先心病的死因和并发症研究

目前对成人先天性心脏病(CHD)死亡经验知之甚少。本研究的目的是评估美国当代人群中成年先心病患者的死亡年龄、心血管并发症的存在以及最常见的死因。

JACC:主动脉瓣反流伴二尖瓣反流的特征研究

二尖瓣反流(MR)加上血流动力学显着的慢性主动脉瓣反流(AR)的病因、机制和存活率目前还不清楚。

Baidu
map
Baidu
map
Baidu
map